ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts

Zhang, Chunlong; Zhang, Yuxi; Tan, Guiyuan; Mi, Wanqi; Zhong, Xiaoling; Zhang, Yu; Zhao, Ziyan; Li, Feng*; Xu, Yanjun*; Zhang, Yunpeng*哈尔滨医科大学
Frontiers in Immunology2022-5-23DOI: 10.3389/fimmu.2022.853074
1被引6阅读
引用收藏
分享

摘要

Glioma is the most common malignant tumor of the central nervous system. Tumor purity is a source of important prognostic factor for glioma patients, showing the key roles of the microenvironment in glioma prognosis. In this study, we systematically screened functional characterization related to the tumor immune microenvironment and constructed a risk model named Glioma MicroEnvironment Functional Signature (GMEFS) based on eight cohorts. The prognostic value of the GMEFS model was also verified in another two glioma cohorts, glioblastoma (GBM) and low-grade glioma (LGG) cohorts, from The Cancer Genome Atlas (TCGA). Nomograms were established in the training and testing cohorts to validate the clinical use of this model. Furthermore, the relationships between the risk score, intrinsic molecular subtypes, tumor purity, and tumor-infiltrating immune cell abundance were also evaluated. Meanwhile, the performance of the GMEFS model in glioma formation and glioma recurrence was systematically analyzed based on 16 glioma cohorts from the Gene Expression Omnibus (GEO) database. Based on multiple-cohort integrated analysis, risk subpathway signatures were identified, and a drug-subpathway association network was further constructed to explore candidate therapy target regions. Three subpathways derived from Focal adhesion (path: 04510) were identified and contained known targets including platelet derived growth factor receptor alpha (PDGFRA), epidermal growth factor receptor (EGFR), and erb-b2 receptor tyrosine kinase 2 (ERBB2). In conclusion, the novel functional signatures identified in this study could serve as a robust prognostic biomarker, and this study provided a framework to identify candidate therapeutic target regions, which further guide glioma patients' clinical decision.

学科与关键词

关键词
gliomaimmune microenvironmentprognosissubpathwaymultiple cohorts
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-05-23
卷期
第 13 卷
页码
853074
DOI
10.3389/fimmu.2022.853074
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [62172131, 62101164]

作者

  • Z

    Zhang, Chunlong (第一作者)

    harbin med univ

  • Z

    Zhang, Yuxi

查看全部 10 位作者收起作者
  • T

    Tan, Guiyuan

    harbin med univ

  • M

    Mi, Wanqi

    harbin med univ

  • Z

    Zhong, Xiaoling

    harbin med univ

  • Z

    Zhang, Yu

  • Z

    Zhao, Ziyan

    harbin med univ

  • L

    Li, Feng (通讯)

    harbin med univ

  • X

    Xu, Yanjun (通讯)

    harbin med univ

  • Z

    Zhang, Yunpeng (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417